INTRODUCTION
In type 2 diabetes hepatic insulin resistance, hyperglucagonaemia and an increased level of gluconeogenic precursors are key factors for the increased hepatic glucose production seen both in the fasting and postprandial states [1, 2] . In the liver, glucose is produced from two pathways : gluconeogenesis (GNG) and glycogenolysis (breakdown of glycogen). The relative contribution of glycogenolysis and GNG to the overall hepatic glucose production has been the focus of many studies in human. However, the studies have resulted in diverging estimates, dependent on the applied method and the length of fasting and the subjects studied [3] [4] [5] [6] [7] . Therefore it is not obvious whether inhibition of hepatic glycogenolysis can normalize the increased hepatic glucose production in type 2 diabetes. However, inhibition of glycogen phosphorylase (GP) (EC 2.4.1.1), the ratecontrolling enzyme of glycogenolysis, has been shown to lower blood glucose levels in an animal model of type 2 diabetes [8] [9] [10] , supporting the hypothesis that inhibition of GP could be a potential pharmacological target for lowering hyperglycemia in patients with type 2 diabetes. Furthermore, studies have shown that a substantial portion of the GNG appears to be cycled through the glycogen pool before efflux from the liver [11] . Also, in hepatocytes a GP inhibitor (CP-92,149) has been shown to decrease glucose production from lactate [8] . Therefore a glyAbbreviations used : CP-320,626, 5-chloro-1H-indole-2-carboxylic acid [1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide ; DAB, 1.4-dideoxy-1.4-imino-D-arabinitol ; 1-GlcNAc, N-acetyl-β-D-glucopyranosylamine ; GNG, gluconeogenesis ; GP, glycogen phosphorylase. 1 To whom correspondence should be addressed (e-mail Btta!novonordisk.com). 2 Present address : Combio A/S c/o Carlsberg Research Center, Gamle Carlsbergvej 10, DK-2500 Valby, Denmark.
inhibited rabbit muscle GPa in synergy when the GPa activity was measured towards glycogenolysis. When GPa activity was measured towards glycogen synthesis, CP-320,626 showed a synergistic effect with glucose, whereas the effect of DAB was slightly antagonized by glucose in this assay direction. Caffeine was included in the investigation as a control GP inhibitor, and both glucose and 1-GlcNAc potentiated the effect of caffeine independent of the assay direction. In primary cultured rat hepatocytes 1-GlcNAc and CP-320,626 inhibited basal and glucagon-induced glycogenolysis in synergy, whereas the ability of DAB to inhibit basal or glucagon-induced glycogenolysis was unaltered by 1-GlcNAc. Glucose had no effect on either CP-320,626 or DAB inhibition of glycogenolysis in cultured rat hepatocytes. In conclusion, the present study shows that the two GP inhibitors are kinetically very distinct and neither of the inhibitors demonstrates a physiologically relevant glucose dependence in itro.
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cogen phosphorylase inhibitor could in principle inhibit glucose from both pathways. Glucose is a physiological regulator of hepatic glycogen metabolism via its effects on both glycogen synthesis and glycogen degradation. Glucose, which binds to the active site of GPa (the phosphorylated and active form of GP), inhibits GPa in a competitive manner by promoting a conformational change of GPa to the less active T-state [12, 13] . The T-state is also a better substrate for protein phosphatase-1, the enzyme responsible for the inactivation of GPa to GPb by dephosphorylation. It has been shown that the glucose analogue N-acetyl-β--glucopyranosylamine (1-GlcNAc), which also binds to the glucose binding site, is a much more potent inhibitor of GPa than glucose [14, 15] . Moreover, glucose and 1-GlcNAc were both able to potentiate the inhibitory action of caffeine on GPa, with 1-GlcNAc being more potent [14] . Another glucose analogue, 1,4-dideoxy-1,4--arabinitol (DAB), has recently been shown to be an inhibitor of GPa both in itro and in i o [10, 16] . From a mechanistic point of view, DAB possesses features other than those of glucose with respect to GPa inhibition [10] . For example, DAB reverses the inhibitory effect of caffeine [10] , whereas 1-GlcNAc and caffeine inhibit GPa in synergy [15] .
5-Chloro-1H-indole-2-carboxylic acid [1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide (CP-320,626), another potent inhibitor of GP, was found to bind to a new allosteric site (the indole binding site) [17, 18] . One of the interesting features of this class of compounds is that their potencies were found to be glucose dependent [8] in a way similar to caffeine [19] . These types of compounds could, in theory, therefore be more effective GP inhibitors in the presence of high plasma glucose compared with low plasma glucose. Thereby, treatment of type 2 diabetes with such compounds would diminish the risk of hypoglycaemia, a major concern of patients with type 2 diabetes.
In the light of the possible role of glucose as a modulator of the potency of GP inhibitors and the physiological relevance of this, the present investigation was undertaken to characterize this in further detail by examining the influence of glucose and 1-GlcNAc on the two GP inhibitors.
MATERIALS AND METHODS

Materials
Male Sprague-Dawley rats were obtained from Møllega/ rd Breeding Center (Lille Skensved, Denmark). Female Yorkshire pigs were obtained from Ellegaard Breeding Center (Dalmose, Denmark). Tissue culture flasks and dishes were purchased from Nunc A\S (Roskilde, Denmark). Collagenase Type IV, collagen Type I (rat tail), glucose oxidase kit, rabbit muscle GPa and all other enzymes and chemicals were purchased from Sigma and Boehringer Mannheim (Hørsholm, Denmark). Dexamethasone was purchased from MSD (Haarlem, The Netherlands). Medium 199, foetal calf serum, Trypan Blue, penicillin and streptomycin were purchased from Life Technologies (Roskilde, Denmark). Human insulin and glucagon were from Novo Nordisk A\S (Bagsvaerd, Denmark). Scintillation fluid Ultima Gold was from Packard Instrument Co. (Meriden, CT, U.S.A.). Protein Assay kit was from Bio-Rad (Copenhagen, Denmark). CP-320,626 was synthesized at Novo Nordisk A\S (Ma/ løv, Denmark) according to procedures described by Hoover et al. [9] . DAB and 1-GlcNAc were synthesized at Novo Nordisk A\S as well.
GP activity
GPa (GPb 5 %) from pig liver was prepared as described previously by Fosgerau et al. [10] . Fed male Wistar rats (approx. 200 g) were anaesthetized with a freshly prepared mixture of Hypnorn (0.05 mg\ml fentalylj2.5 mg\ml fluabizone) and Dormicum (1.25 mg\ml midazolam) (1 : 1) administered subcutaneously (1 ml\kg). After sedation, 50 µg of glucagon was administrated intraperitonally in order to activate GPa ; 4 min later the livers were perfused in situ through the vena porta with 60 ml ice-cold buffer (100 mM glycylglycine, 100 mM NaF and 1 mM EDTA), pH 7.4. The liver was excised and homogenized with a Polytron PT3000 in 30 ml buffer. The unbroken cells and cell debris were separated from the liver homogenate by centrifugation at 8000 g for 10 min at 2 mC. Then the supernatant was centrifuged at 40 000 g for 120 min at 2 mC. After this step, a glycogen pellet containing GPa was homogenized in 5 ml of 1 mM EDTA and stored at k80 mC until assayed.
Glycogen phosphorylase activity (GPa) was measured in the direction of glycogenolysis by determination of NADPH in an assay coupled to phosphoglucomutase and glucose-6-phosphate dehydrogenase. The enzyme activity was assayed at pH 6.8 and 25 mC in a phosphate buffer containing KH # PO % (18 mM), Na # HPO % (27 mM), MgCl # (15 mM), EDTA (100 µM), NADP + (340 µM), glucose 1,6-bisphosphate (4 µM), glucose-6-phosphate dehydrogenase (6000 units\l), phosphoglucomutase (800 units\l) and glycogen (2 mg\ml) [20] . DAB, CP-320,626, caffeine, glucose or 1-GlcNAc had no effect on the enzymes coupled to this assay.
Glycogen phosphorylase (GPa) activity was also measured in the direction of glycogen synthesis using 0.5 mM glucose-1-phosphate as the substrate in a N,N-bis-(2-hydroxyethyl)-2-aminoethanesulphonic acid (50 mM) buffer at pH 6.8, containing glycogen (0.125 %) and EDTA (1 mM) [21] . GP activity was determined at 25 mC by using purine nucleoside phosphorylase and 7-methyl-6-thioguanoside as the auxiliary enzyme and substrate respectively. The product of the reaction, 7-methyl-6-thioguanine, was measured spectrophotometrically at 360 nm. DAB, CP-320,626, caffeine, glucose or 1-GlcNAc had no effect on the coupling enzyme.
Isolation and culturing of hepatocytes
Male Sprague-Dawley rats (approx. 200 g) were anaesthetized with a freshly prepared mixture of Hypnorm (0.05 mg\ml fentalylj2.5 mg\ml fluabizone) and Dormicum (1.25 mg\ml midazolam) (1 : 1) administered subcutaneously (1 ml\kg). Hepatocytes were isolated from rats fed ad lib. using a two-step perfusion technique essentially as described by Seglen [22] . Cell viability, assessed by Trypan Blue exclusion, was consistently greater than 80 %. Cells were plated on to collagen-coated 12-well plates in basal medium (Medium 199 containing 5.5 mM glucose and 0.1 µM dexamethasone, 100 units\ml penicillin, 100 mg\ml streptomycin and 1 nM insulin) supplemented with 4 % foetal calf serum at a cell density of 330 000 cells\well. The medium was replaced with a basal medium 1 h after initial plating in order to remove dead cells, and cells were cultured for 24 h. To study glycogenolysis, after the initial 24 h, the medium was replaced with basal medium supplemented with 9.5 mM glucose and 9 nM insulin to build up glycogen reserves, and experiments were performed 20 h later in the media defined below.
Protein content in the culture dishes was determined after solubilization of the cells in 0.1 M NaOH, using the Bio-Rad protein assay and human serum albumin as standard.
Glycogenolysis
After 20 h of glycogen synthesis, hepatocytes were washed twice with pre-warmed (37 mC) buffer A [117.6 mM NaCl\5.4 mM KCl\0.82 mM Mg # SO % \1.5 mM KH # PO % \20.0 mM Hepes\ 9.0 mM NaHCO $ \0.1 % (w\v) human serum albumin\2.25 mM CaCl # (pH 7.4)] and incubated in buffer A containing increasing concentrations of CP-320,626 or DAB (range 0-20 µM) in the absence (basal conditions) or presence of 2 nM glucagon (stimulated conditions) for 180 min. To determine whether glucose could influence the potency of the GP inhibitors, a nonmetabolizable glucose analogue (1-GlcNAc) was used as a surrogate for glucose. 1-GlcNAc is phosphorylated but not further metabolized [23] . Consequently, glucose released into the medium could be measured directly. Basal and glucagon-induced glycogenolysis were measured as glucose released into buffer A, by using a glucose oxidase kit from Sigma (510-A). Lactate in the medium was determined using the Sigma lactate reagent (735-10). Glycogen levels were determined after two rapid washes of cells with ice-cold 0.9 % (w\v) NaCl by amyloglucosidase (exo-1.4-α--glucosidase) digest, as described by Gomez-Lechon et al. [24] .
To determine the effect of glucose on the potency of the two inhibitors, hepatocytes were pre-incubated with 15 mM glucose traced with [U-"%C]glucose (0.5 µM : Ci : ml −" ) and 10 nM insulin to build up labelled ["%C]glycogen. After 20 h of incubation with radiolabelled glucose, cells were washed three times in prewarmed 0.9 % NaCl and incubated in the presence of increasing concentrations of CP-320,626 or DAB (range 0-25 µM) and glucose (0-12.5 mM) in glucose-free medium 199 in the presence of 0.5 nM glucagon at 37 mC in 5% CO # . After incubation for 90 min, the medium was transferred to scintillation vials and "%C radioactivity was determined by a scintillation counter.
Statistical analyses
Statistical analyses were performed using a one-or two-tailed paired Student's t test (homoscedastic\heteroscedastic, depending upon variance). Statistical significance was evaluated and denoted as follows : *P 0.05 ; **P 0.01 ; ***P 0.001. Replicates (n) were defined as separate hepatocyte preparations and for the enzyme assays as separate determinations. Results are presented as meanspS.E.M.
RESULTS
The roles of glucose and 1-GlcNAc on the inhibitory actions of DAB, CP-320,626 and caffeine were investigated when GPa was analysed in the direction of glycogenolysis. The IC &! values without effectors were calculated from Figure 1 to be 740p9 nM (DAB), 2.39p0.37 µM (CP-320,626) and 20.33p0.93 mM (caffeine). The effect of DAB on GPa activity measured in the presence of glucose (5 mM) or 1-GlcNAc (5 mM) is shown in Figure 1 (A). Glucose had no effect on the potency of DAB, whereas 1-GlcNAc decreased the potency by half at 5 mM. There was no synergistic effect of glucose on the potency of CP-320,626 ( Figure  1B ), whereas 1-GlcNAc was able to increase the potency of CP-320,626 by 10-fold at 5 mM. To verify the results obtained on GPa activity, when measured in the direction of glycogenolysis, caffeine was used as control inhibitor. Caffeine showed synergy with both glucose and 1-GlcNAc in this experimental set-up ( Figure 1C ). In the absence of DAB, CP-320,626 and caffeine, glucose (5 mM) and 1-GlcNAc (5 mM) inhibited GPa by 5 and 50 % respectively. It is therefore not possible to calculate an IC &! value for GPa inhibition by glucose, whereas the IC &! for 1-GlcNAc must be close to 5 mM. Figure 2 (A) shows the relative IC &! values for DAB, CP-320,626 and caffeine in the presence of increasing concentrations of glucose. There was no effect of glucose on the potency of DAB or CP-320,626, whereas the effect of caffeine was potentiated significantly by glucose. Nevertheless, both CP-320,626 and caffeine inhibited rabbit muscle GPa in synergy with glucose when GPa was analysed in the direction of glycogenolysis (Table  1 ). Figure 2 (B) shows that 5 mM 1-GlcNAc antagonized the effect of DAB, whereas 1 mM 1-GlcNAc had no effect. The IC &! value increased by approx. 1.8-fold at 5 mM 1-GlcNAc. On the other hand, CP-320,626 and caffeine inhibited GP in synergy with 1-GlcNAc at both 1 and 5 mM.
Figure 4 Effect of DAB on basal and glucagon-stimulated glycogenolysis in the presence or absence of 1-GlcNAc in primary rat hepatocytes
Hepatocytes were incubated in a glucose-free buffer for 3 h as described in the Methods section. Open symbols indicate experiments performed in the absence of 1-GlcNAc and closed symbols correspond to experiments performed in the presence of 1 mM 1-GlcNAc. (A) Subsequently, basal ( , ) and glucagon-stimulated (#, $) glucose production was measured. 100 % corresponds to basal glucose production in the absence of DAB and 1-GlcNAc and is equal to 543p117 nmol glucose/mg protein. (B) Basal ( , ) and glucagonstimulated (#, $) lactate production was measured ; 100 % corresponds to basal lactate production in the absence of DAB and 1-GlcNAc and is equal to 2323p264 nmol of lactate/mg of protein. (C) After glycogenolysis, glycogen levels after basal ( , ) and glucagonstimulated (#, $) glycogenolysis were determined ; 100 % corresponds to glycogen retained after basal glucose production in the absence of DAB and 1-GlcNAc and is equal to 2140p303 nmol of glycosyl unit/mg of protein. The potency of DAB has been described previously to be dependent on the assay direction of GPa [10] . DAB was less potent when GPa activity was analysed in the direction of glycogen synthesis. The IC &! value increased by two orders of magnitude and was calculated to be 233p6 µM in the present study. By contrast, CP-320,626 was approx. 5 times more potent, with an IC &! of 465p1 nM, which was also the case for caffeine, glucose and 1-GlcNAc, with IC &! values calculated to be
Figure 5 Effect of CP-320,626 on basal and glucagon-stimulated glycogenolysis in the presence or absence of 1-GlcNAc in primary rat hepatocytes
Hepatocytes were incubated in a glucose-free buffer for 3 h as described in the Methods section. Open symbols indicate experiments performed in the absence of 1-GlcNAc and closed symbols correspond to experiments performed in the presence of 1 mM 1-GlcNAc. (A) Subsequently, basal ( , ) and glucagon-stimulated (#, $) glucose production was measured ; 100 % corresponds to basal glucose production in the absence of CP-320,626 and 1-GlcNAc and equals 846p86 nmol of glucose/mg of protein. (B) Basal ( , ) and glucagon-stimulated (#, $) lactate production was measured ; 100 % corresponds to basal lactate production in the absence of CP-320,626 and 1-GlcNAc and is equal to 2558p687 nmol of lactate/mg of protein. (C) After glycogenolysis, glycogen levels after basal ( , ) and glucagon-stimulated (#, $) glycogenolysis were determined ; 100 % corresponds to glycogen retained after basal glucose production in the absence of CP-320,626 and 1-GlcNAc and is equal to 1900p418 nmol of glycosyl unit/mg of protein. 642p7 nM, 11.7p0.7 mM and 160p4.8 µM respectively. Since the potency of the compounds depends on the assay direction, the effect of glucose and 1-GlcNAc on the two inhibitors was studied in the direction of glycogen synthesis. fold to 488p75 µM in the presence of 10 mM of glucose. On the other hand, at all tested concentrations of glucose, CP-320,626 and caffeine showed synergy with glucose. The maximal synergistic effect of glucose was obtained at approx. 5 mM, and the IC &! values for CP-320,626 and caffeine at this concentration of glucose were calculated to be 110p41 and 232p14 nM respectively ; approx. 3 times lower than the value in the absence of glucose in each case. Also, when the glucose analogue 1-GlcNAc was used, the same profiles for the three inhibitors were seen ( Figure 3B ). The concentration of 1-GlcNAc used in the present study was 10 times lower than the concentration of 1-GlcNAc used in the assay where GPa activity was measured towards glycogenolysis, due to the increased potency of 1-GlcNAc. The maximal synergistic effect of 1-GlcNAc on CP-320,626 and caffeine was observed at approx. 100 µM 1-GlcNAc, which is almost 50 times lower than that seen for glucose, in agreement with published results [13, 14] .
To characterize the effects of glucose on the two compounds in a functional model system, the inhibitors were tested in primary cultured rat hepatocytes. The hepatocytes were incubated with 1-GlcNAc as a surrogate for glucose, which allowed measurement of endogenous glucose released into the medium. The maximal effect of 1-GlcNAc on glycogenolysis in hepatocytes was reached at 1 mM 1-GlcNAc (results not shown), and therefore this concentration of 1-GlcNAc was used throughout the study. At this concentration of 1-GlcNAc, basal and glucagon-induced glycogenolysis were inhibited by approx. 25 % (Figures 4 and 5) . Basal and glucagon-stimulated (2.0 nM glucagon) glucose production (A), lactate production (B) and retained glycogen levels (C) after incubation with increasing concentrations of DAB in the presence or absence of 1 mM 1-GlcNAc are shown in Figure  4 Figure 4 (A), substantiating that 1-GlcNAc has no effect on the potency of DAB in hepatocytes. Basal and glucagon-stimulated (2.0 nM glucagon) glucose production (A), lactate production (B) and retained glycogen levels (C) after incubation with increasing concentrations of CP-320,626 in the presence or absence of 1 mM 1-GlcNAc are shown in Figure 5 . The IC &! values for Table 2 .
To further elucidate the effects of glucose on the potency of DAB and CP-320,626 in hepatocytes, cellular glycogen levels were radiolabelled with [U-"%C]glucose before glycogenolysis. After extensive washes of the hepatocytes, counts released into the medium will mainly be a mixture of [U-"%C]glucose, [U-"%C] lactate and, to a minor extent, other carbon-containing metabolites [25] . The amount of glucose and lactate released into the medium has been shown to be a valid measure of glycogenolysis [15] . The counts released into the medium were furthermore inhibited to the same extent each time the experiments were performed, indicating full inhibition of glycogenolysis. Incubation of hepatocytes with increasing concentrations of DAB (A) and CP-320,626 (B) in the presence of increasing glucose concentrations is shown in Figure 6 . The increasing concentrations of glucose did not affect the potency of DAB or CP-320,626. The IC &! values for DAB in the absence or presence of 12.5 mM glucose were calculated to be 0.97p0.42 and 0.97p0.82 µM respectively from Figure 6 (A). The IC &! values for CP-320,626 in the absence or presence of 12.5 mM glucose were calculated to 0.60p0.06 and 0.76p0.31 µM respectively from Figure 6 (B). Glucose inhibited glycogenolysis in a dose dependent manner, by approx. 30 % at 12.5 mM of glucose.
DISCUSSION
Allosteric effectors alter GPa activity by stabilizing either the active (R state) or the inactive state (T state) [12] . Therefore the presence of different allosteric effectors in the two different assays (glycogenolysis and glycogen synthesis) has a major influence on the kinetics of the two inhibitors DAB and CP-320,626. Nevertheless, the results obtained when GPa was analysed in the physiological direction (glycogenolysis) correlates with the results obtained in the primary hepatocytes and emphasis should be put on these results.
The kinetics of DAB was influenced by the direction in which the GPa activity was measured. Whereas glucose had no effect on DAB when GPa activity was measured in the direction of glycogenolysis, glucose antagonized effects of DAB when GPa activity was measured towards glycogen synthesis. One possible explanation for this difference could be related to the lack of potency of DAB in the GPa activity assay measured towards glycogen synthesis. The potency of DAB increased by more than two orders of magnitude when GPa activity was measured in the direction of glycogenolysis, and in this assay glucose had no effect on the potency of DAB. The presence of inorganic phosphate (P i ) in the assay buffer when GPa activity was measured towards glycogenolysis may be of significant importance in terms of potency of DAB (N. Westergaard and B. Andersen, unpublished work).
The effect of glucose on the potency of CP-320,626 was also dependent on the direction in which GPa activity was measured. No synergy was observed between CP-320,626 and glucose when GPa activity was measured towards glycogenolysis, whereas synergy was found when GPa activity was measured in the other direction. However, when the kinetics of caffeine was investigated, synergy with glucose was observed in both assay directions. Difference in the behaviour of CP-320,626 and caffeine is probably a result of their different binding sites [16, 17] . The observed synergistic effect between CP-320,626 and glucose when GPa activity was measured in the direction of glycogen synthesis is in agreement with published results on a structural analogue of CP-320,262 [8] . Also, the synergistic effect of caffeine and glucose is well described [19, 26] .
The IC &! values of DAB, CP-320,626 and caffeine obtained when GPa activity was measured in the two assay directions cannot be directly compared. However, the relative potency of the compounds can be compared. The potency of GP inhibitors are, as shown, highly dependent on the assay direction and conditions. Therefore caution must be exercised when the potency of GP inhibitors described in the literature is compared.
The present study also showed that different isoforms of GPa behave differently in the presence of glucose. As shown in Table  1 , CP-320,626 and caffeine inhibit rabbit muscle GPa in synergy with glucose when GPa activity was measured towards glycogenolysis, opposite results being obtained with pig liver GPa. However, since skeletal muscle has very limited intracellular concentrations of glucose, the increased potency of CP-320,626 on muscle GPa in the presence of glucose has no physiological relevance.
DAB and CP-320,626 have previously been tested in hepatocytes. DAB was found to inhibit hepatic glycogenolysis in primary rat hepatocytes with an IC &! value of approx. 1.1 µM [15] , and CP-320,626 inhibited glycogenolysis in human hepatocytes with an IC &! value of 2.7 µM [9] . The IC &! values for inhibition of glycogenolysis by DAB found in the present study are in accordance with previous reported results [15] . The IC &! value for inhibition of glucagon-induced glycogenolysis by CP-320,626 was approx. 3-fold lower in the present study compared with literature results. However, primary rat hepatocytes were used in the present study compared with primary human hepatocytes used in a previous publication [9] . The two inhibitors inhibited glucose and lactate production to the same extent. However, approx. 20 % (260p6 % compared with 210p7 % of the basal value) more glycogen was retained in hepatocytes treated with 20 µM CP-320,626 compared with hepatocytes treated with 20 µM DAB. A compound structurally related to CP-320,626 was recently found to activate glycogen synthase and thereby to stimulate glycogen synthesis in primary hepatocytes [27] . The stimulatory effect of glycogen synthase has not been observed with DAB ( [15] ; T. Latsis, B. Andersen and L. Agius, unpublished results). Therefore the higher glycogen level retained after treatment with CP-320,626 might be due to a stimulatory effect on glycogen synthesis by CP-320,626.
The effects of 1-GlcNAc were also studied in hepatocytes in order to compare the results obtained for the enzyme with those from a more physiological system. The potency of CP-320,626 but not DAB was affected by 1 mM 1-GlcNAc. The potency of CP-320,626 was increased by approx. 3-fold in the presence of 1 mM 1-GlcNAc in hepatocytes. This correlates well with the results obtained in the enzyme assay (glycogenolysis), where 1 mM 1-GlcNAc increased the potency of CP-320,626 by 5-fold. The results obtained with 1-GlcNAc and DAB also correlate well, since 1 mM 1-GlcNAc had no effect on DAB in the enzyme assay or in the hepatocytes. According to the results for the enzyme in the present study and the literature, 1-GlcNAc is approx. 50-fold more potent than glucose [22] . Therefore CP-320,626 will probably only inhibit glycogenolysis in synergy with glucose at extremely high concentration of glucose (50 mM) in hepatocytes.
In the second cellular assay, utilizing radiolabelled glucose, neither CP-320,626 nor DAB was affected by glucose, at glucose concentrations up to 12.5 mM glucose. This supports the hypothesis that extremely high concentrations of glucose (50 mM) are required to obtain a synergistic effect of CP-320,626 and glucose. The IC &! values calculated using this assay are not significantly different from the IC &! values calculated from Figures 4 and 5. It has not been possible to obtain reliable results on glycogen levels after glycogenolysis in this assay since the presence of varying glucose concentrations in this assay has an effect on the glycogen level.
The role of GP inhibitors in the treatment of hyperglycemia in type 2 diabetes is yet to be determined. However, a considerable amount of data suggest in i o efficacy of GP inhibitors in animal models of diabetes [8] [9] [10] . Also, first results for human models have been published [28] and new results also confirm that inhibition of GP might have a positive effect on hepatic glycogen synthesis [27] and thereby glucose disposal. Furthermore, a glucose-dependent GP inhibitor could be quite important in terms of avoiding hypoglycemia ; however, CP-320,626 showed no synergy with glucose either when GPa activity was measured in the direction of glycogenolysis or in cultured hepatocytes.
Likewise, the potency of DAB was unaffected by glucose when GPa activity was measured in the direction of glycogenolysis and in cultured hepatocytes. In conclusion, neither CP-320,626 nor DAB is affected by physiologically relevant concentrations of glucose in a functional model system.
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